No Data
Laekna Begins Phase I Trial for Obesity Drug in China; Shares Jump 11%
LAEKNA-B (02105.HK): The first subject visit for the multi-dose escalation study of LAE102 for the treatment of obesity has been completed.
Gelonghui, March 26丨LAEKNA-B (02105.HK) announced that the Group has initiated the recruitment of participants for the Phase I multi-dose escalation study ("MAD study") of LAE102 for the treatment of obesity in China. As of the date of this announcement, the first participant has completed the initial visit. The MAD study is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered LAE102 in 60 overweight/obese participants. The Group is committed to bringing this precision treatment to those in need of new treatment options for high-quality outcomes.
Laekna's 2024 Loss Narrows
LAEKNA-B (02105.HK) announced its annual performance and is advancing the development of various innovative drug candidates.
On March 24, Glonghui announced that LAEKNA-B (02105.HK) reported that the company's Other income increased from 16.7 million yuan in 2023 by 21.5 million yuan or 128.7% to 38.2 million yuan in 2024, mainly due to increased interest income from bank deposits in 2024. The company incurred a loss of 0.254 billion yuan for the year, compared to a loss of 0.369 billion yuan in the same period last year. LAE102 is a monoclonal antibody independently developed by the company targeting ActRIIA. Blocking the Activin-ActRII pathway can promote muscle regeneration and reduce fat, which makes LAE1.
Express News | Laekna Inc - Loss for Year RMB254.3 Mln
LAEKNA-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024